KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kura Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$9.36+0.28 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $831.68M
- P/E (TTM)
- –
- Dividend yield
- –
Kura Oncology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Market Cap | $832.67M | $166.30M |
| Enterprise Value | $323.44M | $88.19M |
| PS Ratio | 10.78 | 3.65 |
| PB Ratio | 17.19 | 2.03 |
| P/TBV Ratio | 17.19 | 2.29 |
Enterprise value
| Measure | Kura Oncology | Industry median |
|---|---|---|
| EV / Sales | 4.19 | 2.51 |
Income (trailing twelve months)
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Revenue | $77.23M | $58.34M |
| Operating Income | -$318.09M | -$21.40M |
| Pretax Income | -$296.69M | -$14.34M |
| Net Income | -$296.78M | -$22.46M |
| EBITDA | -$318.09M | -$16.91M |
| EPS (Diluted) | -$3.37 | -$0.83 |
Margins
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Operating Margin | -411.9% | -44.0% |
| Pretax Margin | -384.2% | -13.3% |
| Profit Margin | -384.3% | -40.2% |
| EBITDA Margin | -411.9% | -30.2% |
| FCF Margin | -152.1% | -9.27% |
Returns
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -167.7% | -53.2% |
| Return on Assets (ROA) | -46.7% | -40.9% |
| Return on Capital Employed (ROCE) | -67.7% | -38.1% |
Growth
| Measure | Kura Oncology | Industry median |
|---|---|---|
| FCF Growth (YoY) | -195.6% | 2.34% |
Balance sheet
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $519.03M | $61.43M |
| Total Debt | $9.79M | $118.52M |
| Net Cash (Debt) | $509.24M | $15.35M |
| Net Cash Per Share | $5.72 | $0.66 |
| Equity (Book Value) | $48.43M | $49.09M |
| Book Value Per Share | $0.54 | $1.37 |
| Tangible Book Value | $48.43M | $23.52M |
| Working Capital | $441.25M | $76.81M |
Financial position
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Current Ratio | 4.73 | 3.34 |
| Quick Ratio | 4.47 | 2.44 |
| Debt / Equity | 0.20 | 0.52 |
| Interest Coverage | -224.01 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Operating Cash Flow | -$111.76M | -$12.35M |
| Capital Expenditures | -$5.67M | -$1.08M |
| Free Cash Flow | -$117.43M | -$20.22M |
| FCF Per Share | -$1.32 | -$0.42 |
Efficiency
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Asset Turnover | 0.12 | 0.39 |
| Revenue Per Employee | $297.02K | $404.87K |
| Profits Per Employee | -$1.14M | -$703.34K |
| Employee Count | 260 | 74 |
Dividends and yields
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Earnings Yield | -35.6% | -23.3% |
| FCF Yield | -14.1% | -8.72% |
Shares
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Shares Outstanding | 88,960,600 | 58,127,000 |
| Shares Change (YoY) | 1.17% | 10.9% |
| Shares Change (QoQ) | 0.22% | 0.54% |
| Float | 86,758,500 | 49,136,700 |
| Shares Held by Insiders | 2.48% | 11.6% |
| Shares Held by Institutions | 98.0% | 59.4% |
Taxes
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Income Tax | $84.00K | $79.87K |
Scores
| Measure | Kura Oncology | Industry median |
|---|---|---|
| Altman Z-Score | -2.96 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Kura Oncology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.